Skip to main content
SYRE
NASDAQ Life Sciences

Spyre Reports Q2 2026: $1.1B Cash, Positive Phase 2 Data, and a Wave of Catalysts

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$104.94
Mkt Cap
$9.113B
52W Low
$14.505
52W High
$105.25
52W Position info
623% above low
Off High info
at 52W high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

SYRE has more than doubled off its 52-week low of $14.505.

Summary

Spyre Therapeutics posted Q2 2026 results with $1.1 billion in cash and a net loss of $36.2 million. Positive Phase 2 data for SPY001 and SPY002 were highlighted, along with confirmation of multiple upcoming data readouts, including SPY003 and RA data in September.


Key Events · Earnings and Guidance · SYRE

  • Strong Cash Position

    Cash, cash equivalents, and marketable securities totaled $1.1 billion as of June 30, 2026, providing expected runway into the second half of 2029.

  • Positive Phase 2 Data

    SPY001 and SPY002 achieved primary endpoints in SKYLINE Part A, with clinical remission rates of 40% and 33%, respectively, and a safety profile consistent with in-class comparators.

  • Upcoming Catalysts

    Six proof-of-concept readouts expected in 2026, with SPY003 Part A data and the RA sub-study of SKYWAY anticipated in September, and PsA/axSpA data in Q4.

  • Financial Performance

    Q2 2026 net loss was $36.2 million, with R&D expenses of $65.5 million and G&A of $16.1 million, partially offset by a $40 million gain from a legacy asset milestone.


Analysis · SYRE · Life Sciences

A robust quarter for Spyre Therapeutics, anchored by $1.1 billion in cash that extends the runway into 2029, and positive Phase 2 induction data for SPY001 and SPY002 in ulcerative colitis. The company is poised for six proof-of-concept readouts in 2026, with the next major catalyst—SPY003 Part A data and the RA sub-study of SKYWAY—expected in September. The financial strength and clinical momentum reinforce the investment thesis, though the stock is trading near its 52-week high, suggesting much of the optimism may already be priced in.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 37.5% of the 3713 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, SYRE was trading at $104.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.1B. The 52-week trading range was $14.51 to $105.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

SYRE - Latest Insights

SYRE
Nov 03, 2026, 4:01 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $104.00 info
Change: +$4.27 (+4%) info
Market Cap: $9.877B info
SYRE
Nov 03, 2026, 4:01 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $99.73
Real-time Price: $104.00 info
Change: +$4.27 (+4%) info
Market Cap: $9.877B info
SYRE
Oct 07, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $80.51
Real-time Price: $104.00 info
Change: +$23.49 (+29%) info
Market Cap: $9.877B info
SYRE
Oct 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $80.11
Real-time Price: $104.00 info
Change: +$23.89 (+30%) info
Market Cap: $9.877B info
SYRE
Oct 06, 2026, 11:53 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $81.16
Real-time Price: $104.00 info
Change: +$22.84 (+28%) info
Market Cap: $9.877B info